La vendita allo scoperto per CollPlant Biotechnologies dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di CollPlant Biotechnologies. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

CollPlant Biotechnologies (NASDAQ:CLGN) Azioni, Report sulle vendite allo scoperto

CollPlant Biotechnologies

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies Ltd

WIIM

SATS

EchoStar shares are trading lower following a report suggesting the company is delaying its $183 million interest payment.

Elon Musk blasted what he described as a "massive, outrageous, pork-filled" spending package on Tuesday, calling the <a href="https://www.benzinga.com/markets/25/05/45600358/trumps-big-tax-bill-clears-the-house-30-year-yields-jump-to-5-15-as-bond-market-freaks">bill a "disgusting abomination" </a>
What Happened: In a <a href="https://x.com/elonmusk/status/1929954109689606359">post </a>on X, Musk harshly criticized the latest congressional spending bill and expressed frustration with lawmakers who supported it.
"Shame on those who voted for it: you know you did wrong. You know it," he wrote.
Musk did not name the specific bill, but his timing aligns with a growing backlash against large-scale federal appropriations. His post quickly generated tens of thousands of reactions, with users echoing both support and skepticism.
Commentator Robby Starbuck responded. "Congress has never been more hated… It's largely corrupt, insular, narcissistic and filled with the wrong incentives." He called it a bipartisan failure, especially in "leader$hip."
The Pro America Politics account pushed back on Musk's outrage. "Easy to complain. Harder to propose solutions that can pass and win elections."
The post also circulated alongside a widely shared breakdown of the U.S. budget deficit by year. The figures show the deficit ballooned from $236 billion in 2000 to $1.83 trillion in 2024, reflecting consistent gaps between government spending and revenue.
Why It Matters: In a recent interview, Musk described the Department of Government Efficiency (DOGE) as a &#8220;whipping boy&#8221; for various issues. &#8220;If there was some cut, real or imagined, everyone <a href="https://www.benzinga.com/cannabis/25/06/45714305/elon-musk-says-doge-became-a-whipping-boy-for-everything-real-or-imagined-tesla-ceo-doesnt-agree-with-everything-white-house-does-but-wont-speak-out">would blame DOGE.&#8221;</a>
Musk also said that while he agrees with much of the Trump administration&#8217;s actions, he does not concur with everything. &#8220;I agree with much of what the administration does. But we have differences of opinion.&#8221;
Despite these disagreements, Musk indicated a reluctance to publicly criticize the administration, noting that doing so &#8220;creates a bone of contention.&#8221;
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45714305/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation</a></li>
</ul>
Photo: Shutterstock

Politics

Elon Musk Slams Congressional Spending Bill As A 'Disgusting Abomination'

Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder <a href="https://www.benzinga.com/news/25/02/44049133/last-week-jeff-bezos-lost-3-9-billion-in-a-day-woke-up-3-9-billion-richer-now-its-gone">Jeff Bezos</a> saved $6.2 billion in taxes since 2017. According to an April<a href="https://ips-dc.org/wp-content/uploads/2025/04/amazon_tax_report.pdf"> report </a>by the Institute for Policy Studies, Athena, and PowerSwitch Action. The capital-gains break that produced that haul may dodge President Donald Trump's latest plan to hike levies on America's biggest paychecks.&nbsp;
Trump reportedly asked House Speaker Mike Johnson (R-LA) to craft a 39.6% bracket for annual incomes above $2.5 million, according to the<a href="https://www.nytimes.com/2025/05/08/us/politics/trump-new-tax-bracket.html"> New York Times</a>. However, specialists argue the move nicks salaries while leaving stock-driven fortunes—where billionaires stash most wealth—largely untouched for now and again.
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
<h2 class="wp-block-heading">Capital Gains Cushion</h2>
Sarah Anderson, program director at the progressive Institute for Policy Studies, <a href="https://ips-dc.org/the-tax-debate-whats-in-it-for-jeff-bezos-and-amazon-ceo-andrew-jassy/">said</a> during an April 24 briefing that Bezos would have owed the Treasury $6.2 billion had capital gains been taxed like wages under the 2017 Tax Cuts and Jobs Act, a law set to expire next year. Her team tallied roughly $36.7 billion in Amazon share sales fueling that savings.
&#8220;I&#8217;m not a big fan of doing that,&#8221; Johnson told <a href="https://www.foxnews.com/politics/white-house-quietly-floats-millionaire-tax-hike-proposal-congress-gop-leaders-signal-opposition">Fox News</a> on April 15, rejecting the proposed tax hike, adding, "We're the Republican Party and we're for tax reduction.
Populist pressure is also rising outside Capitol Hill. Former White House chief strategist Steve Bannon <a href="https://www.youtube.com/watch?v=dHI2Vn0hPa0">said</a> at the Semafor World Economy Summit on April 23 that the current tax regime is "not sustainable" and insisted any fix "has to be tax increases on the wealthy," sparking a critical response from anti-tax groups.
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
"It's largely symbolic," said Howard Gleckman, a senior fellow at the Urban-Brookings Tax Policy Center, adding the bracket tweak "won't have a significant revenue effect and certainly not a significant effect on inequality," he <a href="https://fortune.com/2025/05/11/trump-millionaire-tax-inequality-billionaires/">told </a>Fortune.
The reason is simple math. Bezos' official paycheck in 2019 was $81,840 while he ran Amazon. Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg opted for a symbolic annual salary of $1, and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO <a href="https://www.benzinga.com/personal-finance/25/04/44885879/elon-musks-100-per-signature-offer-sparks-5-million-lawsuit-canvasser-says-he-relied-on-these-payments-to-pay-his-bills-but-they-never-came">Elon Musk </a>waived his salary entirely.&nbsp;
Their fortunes come from shares that enjoy a 20% long-term gains rate and can sit untaxed if never sold.
Keeping that concession would also widen Washington's budget hole. According to an April <a href="https://bipartisanpolicy.org/blog/the-new-cost-for-2025-tax-cut-extensions-4-trillion/">analysis </a>by the Bipartisan Policy Center, extending the remaining 2017 tax cuts could swell deficits by around $4.1 trillion over a decade.
Skepticism is already surfacing in the Senate. Finance Committee Chair Mike Crapo (R-ID)<a href="https://omny.fm/shows/hugh-hewitt-podcast/pope-leo-xiv"> told </a>radio host Hugh Hewitt on May 9 he is "not excited about the proposal," reflecting wider GOP unease.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

AMZN

TSLA

Jeff Bezos Saved $6.2 Billion In Taxes Since 2017 — Experts Say Trump's Proposed Hike Won't Touch Capital Gains Loophole

<a href="https://www.gurufocus.com/news/2903793/echostar-sats-delays-183m-interest-payment-amid-fcc-review-sats-stock-news">https://www.gurufocus.com/news/2903793/echostar-sats-delays-183m-interest-payment-amid-fcc-review-sats-stock-news</a>
&nbsp;
EchoStar (<a href="https://www.gurufocus.com/stock/SATS/summary">SATS</a>, <a href="https://www.gurufocus.com/stock/SATS/financials">Financial</a>) has announced in a regulatory filing that it will postpone approximately $183 million in cash interest payments originally due on June 2, 2025. These payments concern three sets of notes: the 5.25% secured notes maturing in 2026, the 5.75% secured notes due in 2028, and the 5.125% unsecured notes set to mature in 2029. The amounts owed are about $72.2 million for the 2026 notes, $71.9 million for the 2028 notes, and $38.4 million for the 2029 notes.

News

Legal

Reported Earlier: 'EchoStar (SATS) Delays $183M Interest Payment Amid FCC Review' - GuruFocus

DLTR

FIVE

Shares of discount stores are trading higher amid possible sympathy with Dollar General after the company reported Q1 financial results.

Dollar General shares are trading higher after the company reported better-than-expected Q1 EPS results and raised its FY25 guidance.

Offerings

IMMX

Immix Biopharma Files For Offering Of Up To $13.5M Shares Of Common Stock

<a href="https://x.com/redditstatus/status/1929976493968650461?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/redditstatus/status/1929976493968650461?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

General

RDDT

Reddit Status Posts On X "We are currently investigating this issue."

AAOI

AEVA

ANET

COHR

DELL

DOCN

FCUV

MASS

NTAP

PCLA

RCAT

SMCI

TTMI

Shares of companies within the broader tech sector are trading higher amid overall market strength due to a rise in NVIDIA, a slight improvement in consumer confidence and as traders await details on potential US trade deals.

BILL

CLSK

Core Scientific, Inc. - Class A Common Stock

CORZ

CRNC

GREE

KARO

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

NTRP

RIOT

SAIH

Shares of software companies are trading higher amid overall market strength due to a rise in NVIDIA, a slight improvement in consumer confidence and as traders await details on potential US trade deals.

<a href="https://downdetector.com/status/reddit/">https://downdetector.com/status/reddit/</a>

Downdetector Says User Reports Indicate Problems At Reddit

Investors with a lot of money to spend have taken a bullish stance on Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HIMS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 65 uncommon options trades for Hims &amp; Hers Health.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 33%, bearish.
Out of all of the special options we uncovered, 12 are puts, for a total amount of $453,745, and 53 are calls, for a total amount of $3,066,660.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $1.0 to $105.0 for Hims &amp; Hers Health over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Hims &amp; Hers Health's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Hims &amp; Hers Health's whale trades within a strike price range from $1.0 to $105.0 in the last 30 days. 
<h3>Hims &amp; Hers Health Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748977392_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$3.8</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$66.00</td>
<td>$165.6K</td>
<td>1.0K</td>
<td>4.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$25.0</td>
<td>$24.3</td>
<td>$25.0</td>
<td>$65.00</td>
<td>$137.5K</td>
<td>189</td>
<td>65</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$25.0</td>
<td>$24.25</td>
<td>$25.0</td>
<td>$60.00</td>
<td>$125.0K</td>
<td>1.1K</td>
<td>83</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$53.65</td>
<td>$52.55</td>
<td>$53.64</td>
<td>$3.00</td>
<td>$112.6K</td>
<td>302</td>
<td>36</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.35</td>
<td>$9.7</td>
<td>$9.83</td>
<td>$58.00</td>
<td>$110.7K</td>
<td>669</td>
<td>541</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Having examined the options trading patterns of Hims &amp; Hers Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Hims &amp; Hers Health</h3>
<ul>
<li>Currently trading with a volume of 103,101,957, the HIMS's price is down by -2.46%, now at $55.37. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>What The Experts Say On Hims &amp; Hers Health</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $43.33.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Sell rating on Hims &amp; Hers Health, maintaining a target price of $30. 
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Neutral, setting a price target of $39. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $61. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Hims &amp; Hers Health, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Market Whales and Their Recent Bets on HIMS Options

Investors with a lot of money to spend have taken a bullish stance on Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MCHP, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Microchip Technology.
This isn't normal.
The overall sentiment of these big-money traders is split between 64% bullish and 28%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $203,318, and 9 are calls, for a total amount of $543,287.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $77.5 for Microchip Technology, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Microchip Technology's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Microchip Technology's significant trades, within a strike price range of $55.0 to $77.5, over the past month.
<h3>Microchip Technology 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748977386_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$2.15</td>
<td>$2.0</td>
<td>$2.15</td>
<td>$60.00</td>
<td>$107.5K</td>
<td>366</td>
<td>763</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$2.25</td>
<td>$2.2</td>
<td>$2.2</td>
<td>$60.00</td>
<td>$72.6K</td>
<td>366</td>
<td>1.0K</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.8</td>
<td>$8.5</td>
<td>$8.5</td>
<td>$65.00</td>
<td>$68.8K</td>
<td>877</td>
<td>24</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.6</td>
<td>$1.4</td>
<td>$1.4</td>
<td>$65.00</td>
<td>$68.6K</td>
<td>1.7K</td>
<td>507</td>
</tr>
<tr>
<td>MCHP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$8.8</td>
<td>$8.7</td>
<td>$8.79</td>
<td>$55.00</td>
<td>$63.3K</td>
<td>906</td>
<td>72</td>
</tr>
</tbody>
</table>

<h3>About Microchip Technology</h3>
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
<h3>Where Is Microchip Technology Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 8,896,292, with MCHP's price up by 0.7%, positioned at $60.42.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 58 days.</li>
</ul>
<h3>Expert Opinions on Microchip Technology</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $61.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS persists with their Buy rating on Microchip Technology, maintaining a target price of $65. 
&#x2A; An analyst from Raymond James downgraded its action to Strong Buy with a price target of $65. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Microchip Technology with a target price of $50. 
&#x2A; An analyst from UBS persists with their Buy rating on Microchip Technology, maintaining a target price of $60. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $66.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Microchip Technology, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

MCHP

Market Whales and Their Recent Bets on MCHP Options

Financial giants have made a conspicuous bullish move on First Solar. Our analysis of options history for First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) revealed 68 unusual trades.
Delving into the details, we found 47% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 13 were puts, with a value of $601,706, and 55 were calls, valued at $2,661,063.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $270.0 for First Solar, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for First Solar's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of First Solar's whale activity within a strike price range from $65.0 to $270.0 in the last 30 days. 
<h3>First Solar 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748977381_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$39.45</td>
<td>$39.0</td>
<td>$39.0</td>
<td>$140.00</td>
<td>$195.0K</td>
<td>391</td>
<td>51</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$39.15</td>
<td>$37.15</td>
<td>$37.85</td>
<td>$140.00</td>
<td>$177.8K</td>
<td>391</td>
<td>54</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$8.9</td>
<td>$8.85</td>
<td>$8.85</td>
<td>$90.00</td>
<td>$144.2K</td>
<td>37</td>
<td>5</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$3.6</td>
<td>$3.45</td>
<td>$3.5</td>
<td>$220.00</td>
<td>$78.2K</td>
<td>2.0K</td>
<td>2.4K</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$97.2</td>
<td>$93.85</td>
<td>$95.44</td>
<td>$65.00</td>
<td>$76.3K</td>
<td>63</td>
<td>16</td>
</tr>
</tbody>
</table>

<h3>About First Solar</h3>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
<h3>Present Market Standing of First Solar</h3>
<ul>
<li>With a trading volume of 2,922,156, the price of FSLR is down by -0.37%, reaching $149.1.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 56 days from now.</li>
</ul>
<h3>What Analysts Are Saying About First Solar</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $222.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for First Solar, targeting a price of $204. 
&#x2A; An analyst from Wolfe Research has elevated its stance to Outperform, setting a new price target at $221. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on First Solar with a target price of $157. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on First Solar with a target price of $255. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Outperform rating on First Solar with a target price of $275. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest First Solar options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

FSLR

Spotlight on First Solar: Analyzing the Surge in Options Activity

AVGO

AXTI

CRDO

CSIQ

ENPH

ENTG

INTC

NVDA

NXPI

WKEY

WOLF

Shares of semiconductor companies are trading higher amid overall market strength due to a rise in NVIDIA, a slight improvement in consumer confidence and as traders await details on potential US trade deals.

CrowdStrike Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares are trading higher Tuesday ahead of the company's <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45745176/crowdstrike-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-3">first-quarter earnings report</a>.
What To Know: CrowdStrike is expected to report revenue of $1.16 billion and earnings per share of 81 cents after the market closes on Tuesday. In the previous quarter, the company beat earnings estimates, but missed slightly on revenue and its share price fell 6% the following day. Investors will be paying close attention to both earnings results and forward guidance as <a href="https://www.benzinga.com/news/earnings/25/05/45658340/sentinelone-q1-earnings-revenue-beat-eps-in-line-shares-dive-on-soft-guidance">cybersecurity results</a> have been mixed over the past month. 
Wedbush analyst Daniel Ives maintained an Outperform rating and lifted the price target from $475 to $525 on Tuesday.
Rosenblatt analyst Catharine Trebnick reiterated a <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45725122/crowdstrike-analyst-raises-price-target-ahead-of-q1-results-benefits-from-stable-cybersecurity-budgets-despite-macro-uncertainty">Buy rating</a> and raised the price target from $450 to $515 ahead of earnings, citing consistent demand for cybersecurity services and growing IT consolidation trends that benefit platform-based security vendors like CrowdStrike.
Despite macroeconomic uncertainty, security budgets have remained stable, supported by reseller feedback and industry surveys. Trebnick pointed out that companies are continuing to seek out integrated platforms to simplify operations and reduce risk exposure, which puts CrowdStrike in a favorable position.
The price target increase also reflects a broader expansion in valuation multiples across the cybersecurity sector, which have risen approximately 31% over the past two months. CrowdStrike's Falcon platform, which delivers cloud-native security across endpoints, workloads and identities, has positioned the company to benefit from the trend toward unified security solutions.
Compared to its peers, CrowdStrike leads in revenue growth and gross profit but lags in return metrics such as ROE and ROA. Still, analysts maintain an overall positive outlook, with the company currently holding an Outperform consensus rating across analyst coverage.
CRWD Price Action: CrowdStrike shares were up 1.77% at $487.63 at the time of publication Tuesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a> CrowdStrike shares are up more than 42% year-to-date heading into Tuesday&#8217;s print.
Read Next:
<ul class="wp-block-list">
<li><a href="EXCLUSIVE: May's 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank? 
">EXCLUSIVE: May&#8217;s 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank? </a></li>
</ul>
Image Via Shutterstock.

Earnings

Previews

Movers

CRWD

CrowdStrike Stock Climbs To New Highs Ahead Of Q1 Earnings: What To Know

Across the recent three months, 8 analysts have shared their insights on Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $69.62, a high estimate of $92.00, and a low estimate of $59.00. Observing a downward trend, the current average is 0.54% lower than the prior average price target of $70.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1748977277_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Incyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$72.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Incyte. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Incyte's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Incyte's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Incyte analyst ratings.</a>
<h2>Get to Know Incyte Better</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Incyte: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 19.53%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Incyte's net margin excels beyond industry benchmarks, reaching 15.03%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Incyte's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.45%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.83%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

INCY

Where Incyte Stands With Analysts

In the current session, the stock is trading at $345.57, after a 0.01% increase. Over the past month, Quanta Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) stock increased by 12.10%, and in the past year, by 29.05%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1748977262_0.png" alt="Past Year Chart" />

<h3>Quanta Services P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 50.47 in the Construction &amp; Engineering industry, Quanta Services Inc. has a higher P/E ratio of 55.73. Shareholders might be inclined to think that Quanta Services Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748977262_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Quanta Services Inc's Price Over Earnings

Ratings for NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.83, a high estimate of $8.10, and a low estimate of $3.50. Highlighting a 12.66% decrease, the current average has fallen from the previous average price target of $5.53. 
<img src="https://www.benzinga.com/files/images/story/2025/1748977257_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of NIO by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.50</td>
<td>$4.20</td>
</tr>
<tr>
<td>Jeff Chung</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.10</td>
<td>$8.90</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.20</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to NIO. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of NIO compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for NIO's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into NIO's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NIO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NIO analyst ratings.</a>
<h2>Discovering NIO: A Closer Look</h2>
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.
<h3>NIO's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: NIO's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 15.2%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: NIO's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -36.2% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): NIO's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -82.38%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): NIO's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.74%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 5.67, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NIO Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Across the recent three months, 5 analysts have shared their insights on Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.2, along with a high estimate of $29.00 and a low estimate of $11.00. Observing a downward trend, the current average is 15.74% lower than the prior average price target of $21.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1748977249_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Ameresco. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$11.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ameresco. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ameresco compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Ameresco's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ameresco's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AMRC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ameresco analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Ameresco</h2>
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.
<h3>Financial Milestones: Ameresco's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ameresco's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 18.24%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1.56%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.54%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ameresco's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.13%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.76, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRC

Analyst Expectations For Ameresco's Future

Press Releases

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Small Cap

CollPlant Biotechnologies Provides a Corporate Update

CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

Comments

CollPlant Biotechnologies

Vendite allo scoperto

CollPlant Biotechnologies (NASDAQ:CLGN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO